Researchers question process for reviewing coverage of 'off label' cancer drug use

August 25, 2016

CHAPEL HILL - A group of University of North Carolina Lineberger Comprehensive Cancer Center researchers is calling for an overhaul of the process that determines which cancer drugs used off-label -- or beyond their approved use -- are reimbursed by federally-funded health insurance in the United States.

In a paper published online by the Journal of the American Medical Association, the physician-researchers raised concerns that there are inconsistencies between the five reference guides, or compendia, that the Centers for Medicare and Medicaid Services uses to determine which drugs it will reimburse for off-label uses in cancer care. They also cited the "weak quality" of evidence used in some cases to green-light some off-label uses in oncology, which they argue could be leading to poor quality of patient care and high costs.

"The quality and consistency of these very important compendia resources is not what it should be, given the level of scrutiny that's appropriate for highly toxic and expensive cancer drugs," said the study's corresponding author Ethan Basch, MD, MSc, director of UNC Lineberger Comprehensive Cancer Center's Cancer Outcomes Research Program and a professor in the UNC School of Medicine Division of Hematology/Oncology. "We could be causing substantial suffering for cancer patients because of the sometimes cavalier use of off-label drugs. A new, more rigorous approach is warranted in order to protect our patients."

The researchers report that off-label use of drugs is widely practiced in oncology care. A 2013 study found that off-label uses accounted for $5 billion in cancer drug costs in 2010.

"Off-label drugs are used in many different scenarios in cancer care," said William Wood, MD, MPH, a UNC Lineberger member, an associate professor in the UNC School of Medicine Division of Hematology/Oncology and a co-author of the study. "They can be used if treatment options are limited in a certain situation, or if a clinician wants to try something unconventional, which could be a high quality decision or a poor quality decision. The concern is that people could be getting treatments that are inappropriate and that the risks may be greater than the benefits of these treatments."

Federal law specifies that the Centers for Medicare & Medicaid Services should pay for a drug not used in accordance with the U.S. Food and Drug Administration's label when one of the five reference guides states the drug's off-label use is medically appropriate. Private insurers often use the compendia recommendations to inform coverage decisions, they also report.

But the authors write that previous research has found that the quality of evidence in the reference guides used is sometimes less rigorous than standards for FDA-approved drug uses. In their own analysis of off-label uses for cancer drugs, Basch and his colleagues found limitations in the level, quantity, consistency, and timeliness of evidence cited.

The researchers offer four steps for improving the review process: develop methodological standards for evaluating evidence used to back off-label drug recommendations; combine the findings into one "single, rigorously developed resource" rather than five inconsistent reference guides; assess whether those reviewing and determining off-label drug use policies have potential financial conflicts of interest; and make the compendia listings, which currently are only available by subscription, free to the public.

They also recommended that the FDA, or a public-private partnership, should oversee the decision-making process. "The FDA has the ability to review evidence using strict standards, and the purview of the FDA over oncology is increasing with the development of the FDA Oncology Center of Excellence," Basch said. "We are advocating for an approach that would be different from regular drug approval, but improving on the current system."
-end-
Angela K. Green, MD, MSc, formerly of the UNC Lineberger's Cancer Outcomes Research Program and the UNC School of Medicine who is now at the Memorial Sloan Kettering Cancer Center, was also a co-author of the viewpoint.

UNC Lineberger Comprehensive Cancer Center

Related Cancer Drugs Articles from Brightsurf:

New analysis method can lead to better cancer drugs
While proteins on the surface of cells are the targets for most drugs, refined methods are needed to analyse how these membrane proteins are organised.

High cost of cancer drugs not always justified
Do high prices of some cancer medicines have a higher benefit than those drugs with lower prices?

What are the environmental impacts of cancer drugs?
Chemotherapeutic drugs, also known as antineoplastic agents, that are prescribed to treat a range of cancer types, enter the aquatic environment via human excretion and wastewater treatment facilities.

Careless cancer cells may be susceptible to future drugs
Could the ability of cancer cells to quickly alter their genome be used as a weapon against malignant tumors?

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Dozens of non-oncology drugs can kill cancer cells
Researchers tested approximately 4,518 drug compounds on 578 human cancer cell lines and found nearly 50 that have previously unrecognized anti-cancer activity.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

Scientists find a new use for already known anti-cancer drugs
The world scientific community is waging a difficult and prolonged war on cancer.

Using a chip to find better cancer fighting drugs
Kyoto researchers have developed a new 'tumor-on-a-chip' device that can better mimic the environment inside the body, paving the way for improved screening of potential cancer fighting drugs.

Repurposing heart drugs to target cancer cells
This study has highlighted a novel senolytic drug - drug that eliminates senescent cells -- that are currently being used to treat heart conditions that could be repurposed to target cancer cells, and a range of other conditions.

Read More: Cancer Drugs News and Cancer Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.